1 / 11

Jeffrey Chou EE235

Nanoimprint Lithography Based Fabrication of Shape-Specific Enzymatically -Triggered Smart N anoparticles. Jeffrey Chou EE235. Papers Reviewed.

jada
Download Presentation

Jeffrey Chou EE235

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nanoimprint Lithography Based Fabrication of Shape-Specific Enzymatically-Triggered Smart Nanoparticles Jeffrey Chou EE235

  2. Papers Reviewed [1] Luz Cristal Glangchai, Mary Caldorera-Moore, Li Shi, Krishnendu Roy, Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles, Journal of Controlled ReleaseVolume 125, Issue 3, , 11 February 2008, Pages 263-272. • [2] J.A. Champion, Y.K. Katare and S. Mitragotri, Particle shape: a new design parameter for micro-and nanoscale drug delivery carriers, J. Control. Release121 (1–2) (2007), pp. 3–9.

  3. Basic Idea Insert to Cells PEGDA Enzyme Release Drug Encapsulation

  4. Nanoimprint Fabrication PEGDA Applied to silicon Quartz template pressed onto PEGDA Remove template Oxygen etch to remove residual layer Particles harvested by water buffer.

  5. Shape Variability for Delivery • Shape form factors, aspect ratios, or edges affect particle transport. • Eg: Cell membrane interaction is heavily dependent on shape of particle. 50nm -> 400nm particles

  6. Shape Dependence • With nanoimprint, a wide variety of shapes and depth can be made for custom drug delivery.

  7. Drug Encapsulation • Fluorescently labeled antibodies were trapped within 400nm nanocarriers. • After releasing, particles remained intact by retaining its fluorescence. • Shows that encapsulation does not degrade drug

  8. Enzyme Based Release • PEGDA is mixed with an enzymatically degradable peptide GFLG • GFLG Sensitive to Cathepsin B enzyme • Which is present in lung, ovarian, and colorectal tumor cells. • Other peptides can be used for other diseases • Eg: Breast cancer cells have high concentrations o f Cathepsin D enzyme

  9. Enzyme Release • Cathepsin B based biodegradable encapsulation • (a) No Cathepsin B • (b) 30min. In Cathepsin B • (c) 12h in Cathepsin B • (d) 48h in Cathepsin B

  10. Basic Idea Insert to Cells PEGDA Enzyme Release Drug Encapsulation

  11. Conclusion • Demonstrated the potential for enzyme based nano drug delivery method for cells. • PEGDA and drugs can be easily mixed. • Nanoimprint allows for small particles (~50nm) to be internalized by cells. • Enzyme based release allows for “smart” drug delivery.

More Related